Department of Radiology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, 030009, Shanxi, China.
Department of Physiology, College of Basic Medicine, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Cardiovasc Drugs Ther. 2024 Oct;38(5):977-997. doi: 10.1007/s10557-023-07461-0. Epub 2023 May 13.
Presently, there are many drugs for the treatment of atherosclerosis (AS), among which lipid-lowering, anti-inflammatory, and antiproliferative drugs have been the most studied. These drugs have been shown to have inhibitory effects on the development of AS. Nanoparticles are suitable for AS treatment research due to their fine-tunable and modifiable properties. Compared with drug monotherapy, experimental results have proven that the effects of nanoparticle-encapsulated drugs are significantly enhanced. In addition to nanoparticles containing a single drug, there have been many studies on collaborative drug treatment, collaborative physical treatment (ultrasound, near-infrared lasers, and external magnetic field), and the integration of diagnosis and treatment. This review provides an introduction to the therapeutic effects of nanoparticles loaded with drugs to treat AS and summarizes their advantages, including increased targeting ability, sustained drug release, improved bioavailability, reduced toxicity, and inhibition of plaque and vascular stenosis.
目前，有许多治疗动脉粥样硬化（AS）的药物，其中降脂、抗炎和抗增殖药物的研究最多。这些药物已被证明对 AS 的发展具有抑制作用。由于具有精细可调且可修饰的特性，纳米颗粒非常适合用于 AS 治疗研究。与药物单药治疗相比，实验结果已证明，纳米颗粒包封药物的效果明显增强。除了含有单一药物的纳米颗粒外，还有许多关于协同药物治疗、协同物理治疗（超声、近红外激光和外磁场）以及诊断和治疗一体化的研究。本综述介绍了载药纳米颗粒治疗 AS 的治疗效果，并总结了其优点，包括提高靶向能力、持续释放药物、提高生物利用度、降低毒性以及抑制斑块和血管狭窄。
